Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid;Ergebnisse einer Umfrage an deutschen Hautkliniken zur Therapie von Pemphigus und bullösem Pemphigoid

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 3, 2009, Pages 227-233

  Hofmann, Silke C ^a,e   Kautz, Ocko ^a   Hertl, Michael ^b   Sticherling, Michael ^c   Zillikens, Detlef ^d   Bruckner Tuderman, Leena ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bullous dermatoses; Corticosteroids; Immunosuppressive drugs

Indexed keywords

AZATHIOPRINE; CLOBETASOL PROPIONATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TETRACYCLINE; TRIAMCINOLONE ACETONIDE;

ARTICLE; BULLOUS PEMPHIGOID; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG SAFETY; GERMANY; HEALTH SURVEY; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LOW DRUG DOSE; PATIENT MONITORING; PEMPHIGUS; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; REMISSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

DERMATOLOGY; GERMANY; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; PEMPHIGOID, BULLOUS; PEMPHIGUS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 61449121097     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06872.x     Document Type: Article

References (29)

1. Eming R, Hertl M. Autoimmune bullous disorders. Clin Chem Lab Med 2006 44 : 144 149.
2. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007 11 : 462 481.
3. Goebeler M, Sitaru C, Zillikens D. Blistering autoimmune dermatoses (II): therapy. J Dtsch Dermatol Ges 2004 2 : 774 791.
4. Hertl M, Schuler G. Bullous autoimmune dermatoses. 3: Diagnosis and therapy. Hautarzt 2002 53 : 352 365.
5. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004 122 : 1091 1095.
6. Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudlo C, Pawelczyk B, Messmer EM, Schuhmann M, Sinkgraven R, Buchner L, Budinger L, Pfeiffer C, Sticherling M, Hertl M, Kaiser HW, Meurer M, Zillikens D, Messer G. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002 138 : 903 908.
7. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P, Bernard P. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002 346 : 321 327.
8. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Interventions for bullous pemphigoid. Cochrane. Database. Syst. Rev. 2005 CD002292.
9. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi SZ, Seirafi H, Nazemi MJ, Mortazavi H, Mirshams-Shahshahani M. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007 57 : 622 628.
10. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002 147 : 214 221.
11. Guillaume JC, Vaillant L, Bernard P, Pi-card C, Prost C, Labeille B, Guillot B, Foldes-Pauwels C, Prigent F, Joly P. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993 129 : 49 53.
12. Williams H. Evidence-based Dermatology. 2nd Edition. Blackwell Publishing, 2008 : 573 580 and 581 594.
13. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Luger TA. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofe-til for the treatment of pemphigus. Arch Dermatol 2006 142 : 1447 1454.
14. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Bonsmann G, Luger TA. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007 143 : 1536 1542.
15. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996 10 : 77 84.
16. Schmidt E, Kraensel R, Goebeler M, Sinkgraven R, Brocker EB, Rzany B, Zillikens D. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005 76 : 205 209.
17. Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, Jacobus D. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2008 144 : 25 32.
18. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994 130 : 753 758.
19. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988 119 : 73 77.
20. Rose E, Wever S, Zilliken D, Linse R Haustein UF, Brocker EB. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005 3 : 200 206.
21. Mentink LF, Mackenzie MW, Toth GG, Laseur M, Lambert FP, Veeger NJ, Ci-anchini G, Pavlovic MD, Jonkman MF. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006 142 : 570 576.
22. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 139 : 1051 1059.
23. Herd M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hof-mann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfutze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticher-ling M, Wolff-Franke S. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008 6 : 366 373.
24. Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Herd M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, Schmidt E, Shimanovich I, Michael M, Ziller F. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007 5 : 881 887.
25. Hofmann SC, Thoma-Uszynski S, Hunziker T, Bernard P, Koebnick C, Stauber A, Schuler G, Borradori L, Herd M. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002 119 : 1065 1073.
26. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002 147 : 261 265.
27. Kitajima Y. Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus. Arch Dermatol Res 2003 295 Suppl 1 : S17 S23.
28. Stamm G, Thivolet J. Weaning of systemic steroid treatment in pemphigus. Eur J Dermatol 1995 5 : 664 670.
29. Pfutze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007 17 : 4 11.